ReviewFrontiers in oncology2026
Mechanistic insights and molecular therapy for neuroendocrine prostate cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer with a poor prognosis, strongly associated with androgen deprivation therapy. Recent studies have revealed that neuroendocrine transdifferentiation in NEPC is influenced by both transcription factor activity and epigenetic regulation. This review systematically discusses the origin hypotheses, molecular subtypes, driving mechanisms, and therapeutic strategies of NEPC, focusing on the critical roles of transcription factors and epigenetic modifications in lineage plasticity. Furthermore, we summarize the latest advancements in targeted therapies. By integrating multiomics data and preclinical models, this review provides a theoretical foundation for precision treatment of NEPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.